glp 1 and ovarian cancer Association between glucagon-like peptide-1 receptor agonists survival: A population-based cohort study GLP-1s in Oncology: Exploring Risks

This is sometimes called microdosing. Its important to know that: This is not an FDA-approved indication for GLP-1 medications

The safety of Semaglutide GLP-1 has not been established in pregnant or breastfeeding women

Additionally, some patients experience increased urination while on GLP-1 medications

In STEP 1 [1] , the largest trial with 1,961 participants [1] , patients receiving semaglutide 2.4 mg weekly achieved an average weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021)

The FDA added it to the Category 2 bulk drug substance list in 2023, blocking compounding pharmacies from producing it